It is a BiTE that binds both CD19 (consistently found on ALL blasts) and CD3 (on cytotoxic T-cells) facilitating malignant cell lysis [49]. The second bsAB for treatment of cancer, amivantamab, was approved in 2021 for non-small cell lung cancer (NSCLC). Amivantamab targets EGFR and ...